PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
Completed · Phase 1
Conditions studied: NASH - Nonalcoholic Steatohepatitis
In brief
This is an open-label, single-dose study to evaluate the PK profile of the liquid SC formulation of BIO89-100 in approximately 8 male and female subjects with NASH with compensated cirrhosis.
Key facts
- Study ID
- NCT05022693
- Run by
- 89bio, Inc.
- People needed
- 8
- Starts
- 2021-08-16
- Expected to finish
- 2021-12-21
- Last updated by the study team
- 2022-03-02
Who can join
Age: 21 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- 89bio Clinical Study Site — Chandler, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.